Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Articles

A new study highlights the significant long-term improvements in lesions and scarring of a clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% formulation.

Triple-Combination Acne Gel Demonstrates Long-Term Safety and Efficacy

Maddi Hebebrand is an associate editor of 

and joined the MJH Life Sciences team in May 2024. She attended Baldwin Wallace University, studying Media Production and Film, and received her Masters in Digital Media from Ohio University. When she's not writing, Maddi loves to read, attend concerts and spend time with her family. 

Psoriasis significantly impacts sleep health, with diverse populations facing increased risks of sleep disorders, highlighting urgent clinical needs for tailored interventions.

Psoriasis Linked to Sleep Disorders in Diverse Adults

The study offers reassurance regarding the safety profile of JAKis in patients with severe atopic dermatitis, particularly concerning their impact on venous thromboembolic events.

No Link Found Between JAK Inhibitor Use and Unprovoked Venous Thromboembolisms in Adults with Atopic Dermatitis

Discover how Julia Zimmermann, PD, PhD's PHLAS innovates cold plasma technology for skin care, enhancing treatments for acne and skin health.

 Julia Zimmermann PD, PhD, Demonstrates PHLAS, A New Cold Plasma Skin Care Device

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

Alexandra Kimball, MD, FAAD, reviews late-breaking data at AAD on lutikizumab for hidradenitis suppurativa. 

Late-Breaking Data: Lutikizumab Shows Positive Results in Difficult-to-Treat HS After Failed TNF Therapy 

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

On May 14, The Skin Cancer Foundation held its signature annual fundraising Champions for Change Gala at the Ziegfeld Ballroom in New York City. The event raised more than $800,000 to support the organization’s educational campaigns, community programs and research initiatives.

More than 400 guests attended, including The Skin Cancer Foundation donors, industry and physician allies, celebrity supporters and members of the media. Notable guests included Brendan Fraser, Diane Lane and Uma Thurman. Actress, entrepreneur and author Christie Brinkley hosted the evening and shared her personal skin cancer journey with guests in her opening remarks.

“I imagine no one feels ready to hear that they have skin cancer for the first time, and neither was I,” Brinkley said. “It felt very personal. I hope that sharing my story changes that experience for others and reminds them to protect the lovely skin they are in.”

In line with the theme for The Skin Cancer Foundation’s annual Journal this year, the Foundation debuted a video during the evening called “Skin Cancer Is Personal” that features the stories of skin cancer warriors. President Deborah S. Sarnoff, MD

 also spoke about how the Foundation provides support and resources for newly diagnosed patients during her speech.

“As doctors, we have limited time during our busy days to be able provide additional support for the patient’s journey beyond their appointment,” said Sarnoff. “That’s why The Skin Cancer Foundation has become such an important partner for dermatologists. We’re so grateful for all our corporate partners, friends and donors, as well as the members of the media, who come together to support our work each year.”

The Foundation awarded its annual Media Impact Award to HealthCentral, the flagship website of HealthCentral Corporation. A leading media platform for patients living with chronic or serious illnesses, HealthCentral partnered with the Foundation on its “Skin Cancer in Skin of Color” campaign, a series of educational online articles and social media posts focused on the prevention, detection, and treatment of skin cancer in people of color.

Next, the Foundation recognized its Photobiology Committee, a group of experts in the study of the interaction of ultraviolet radiation and the skin. These dermatologists define the Foundation’s sun protection guidelines and set the criteria for products in the 

. Committee members volunteer their time and expertise to the Foundation, and each year they review third-party testing data for hundreds of sun-protective products to determine if they qualify for the Seal. Steven Q. Wang, MD, director of dermatologic oncology, chief of dermatology at Hoag Memorial Hospital Presbyterian and chair of The Skin Cancer Foundation Photobiology Committee, accepted this special recognition on behalf of the Committee.

The evening culminated with the Champions for Change Award presentation recognizing La Roche-Posay, which has been a member of the Foundation’s Corporate Council since 2007. Many of its sun protection products have earned the Foundation’s Seal of Recommendation. For the past 15 years, La Roche-Posay has supported the fight against skin cancer through its annual public health awareness and educational campaign, SOS — Save Our Skin, which educates the public on the dangers of UV rays, develops broad-spectrum sunscreens suitable for all skin tones and types, and encourages easy integration of sun protection into daily life, including annual skin cancer screenings. Tyler Steele, vice president of medical relations, La Roche-Posay/CeraVe/Vichy, accepted the award on the company’s behalf.

The event co-chairs were April Franzino, Stephanie Schweitzer and Adam Schweitzer. The event’s physician co-chairs were Elizabeth K. Hale, MD, Julie K. Karen, MD, Jesse M. Lewin, MD, and Ariel Ostad, MD. The honorary chair was Marcia Robbins-Wilf, EdD. The Gala Committee included Steve Alperin, Kim Campbell, Ian Michael Crumm, Michelle Henry, MD, Susan Manber, Blair Murphy-Rose, MD, Kim M. Nichols, MD, Ana Prodanovich, Kathy Sabine, Maral K. Skelsey, MD, Susan Small, Tyler Steele, Mary L. Stevenson, MD, Catherine Strange Warren, and Jane Y. Yoo, MD. The Foundation also recognizes its event sponsors: Castle Biosciences, EltaMD Skin Care, La Roche-Posay, and Regeneron Pharmaceuticals, Inc.

The Skin Cancer Foundation's gala raises over $800,000, featuring Christie Brinkley and highlighting vital skin cancer awareness initiatives and personal stories.

The Skin Cancer Foundation Raises $800,000 at Annual Champions for Change Gala

At the 2023 Society of Dermatology Physician Assistants (SDPA) Annual Summer Dermatology Conference in Boston, Massachusetts, 

, a medical director for Novartis who has also been a practicing dermatology physician assistant (PA) for more than 20 years. At the meeting, Mast presented, "Disease State and Unmet Needs in Hidradenitis Suppurativa," where she discussed how to care for patients with hidradenitis suppurativa. 

 What do you hope attendees take away from your talk, "Disease State and Unmet Needs in Hidradenitis Suppurativa?"

. We know that they oftentimes end up in ERs and urgent cares, and so we're really trying to change that with HS awareness. Of course, we in dermatology do a great job of diagnosing these patients. But how can we get them to dermatology sooner and faster?

 What is the importance of awareness and recognition in HS?

 We hear often from patients that there is a long-standing history that they feel shame with this disease. It's very hard for them; it takes a lot of courage to see someone to begin with. And so I think just having empathy is the first thing that I've heard that everybody can do for these patients, is really showing that empathy for what they've been through and their journey, and that's really where we're trying to shine a light on HS, because we know that it's been hidden in the shadows, and we're trying to make these people comfortable to come and get help.

 Why is it such an exciting time in HS research and care?

 I think just the fact that there's a lot more research dollars going into this disease. I hope that one day this diseases is like psoriasis, that now we have a ton of different therapies for the disease. I think we're just at the tip of the iceberg for that. The fact that we're caring for these patients, that we're showing empathy and understanding them, I'm very excited about the future.

Understanding the disease, the pathophysiology better, and then also all the different treatments, because we know that this is a not a one treatment disease. Multimodal treatment is often needed, and surgical and medical management, and so being confident in both of those therapies, and partnering with the patient, will get them the best care.

Hidradenitis suppurativa (HS) patients face significant diagnostic delays, often seeking care in emergency settings. Increasing awareness and empathy are crucial to improving patient experiences and outcomes. The current landscape of HS research is promising, with increased funding and a focus on understanding the disease's pathophysiology. This progress is paving the way for diverse treatment options, similar to advancements seen in psoriasis care. A multimodal approach, combining surgical and medical management, is essential for effective HS treatment, emphasizing the importance of patient-provider partnerships.

Click here to answer this week's HS poll. 

Polls 

POLL: What is the Average Diagnosis Delay for Patients With HS?

Mr George Johnson is a 68-year-old retired preschool teacher who presents a persistent pruritic rash, and a history of recurrent cardiovascular events, including a myocardial infarction 2.5 years ago. He reports a history of atopic dermatitis that has been relatively well controlled until recently; the itching has become more irritating, and he reports sleep disturbances as a result.

Physical examination reveals tractable facial erythema and lateral eyebrow shedding (Hertoghe’s sign). Lichenification is evident on extended sides of the elbows and knees. The patient's skin appears generally dry.

Patient and caregiver education highlighting proper bathing practices (eg, avoid hot baths, reduce frequency) and regular application of moisturizers.

Low dose of calcineurin inhibitors ointment mixed with an emollient. 

First-generation antihistamines before bedtime, with cautious monitoring. 

A biologic (eg, dupilumab or tralokinumab). 

George Johnson, a 68-year-old retired preschool teacher, presents with a persistent pruritic rash and a history of recurrent cardiovascular events, including a myocardial infarction 2.5 years ago. His atopic dermatitis, previously well-controlled, has worsened, causing significant itching and sleep disturbances. Physical examination reveals facial erythema, lateral eyebrow shedding (Hertoghe’s sign), and lichenification on the elbows and knees. His skin is generally dry, indicating a possible exacerbation of his dermatological condition, potentially linked to his cardiovascular history and current symptoms.

What would you suggest or prescribe for these AD symptoms in a 68-year-old man? Test your knowledge and take a look at new data on AD in older patients.

DermIQ 

The Gray Area: A Challenging Case of AD in an Older Patient

Hyperhidrosis is not rare. According to the 

, approximately 385 million people worldwide live with hyperhidrosis.

In fact, they note that the amount of people living with chronic, excessive sweating is even higher than the amount of people living with other dermatologic conditions like psoriasis.

Just how common is hyperhidrosis in real-world comparisons?

The prevalence of hyperhidrosis is much higher in younger populations than in the general population, with 8.8% of individuals between the ages of 18 to 39 years old living with the condition. 

When comparing these statistics to everyday, common occurrences like hair color, the number of people with hyperhidrosis is greater than the 1% of individuals with natural red hair and 2% of individuals with natural blond hair. 

Despite how common hyperhidrosis is, it is estimated that 27% of those with the condition never receive a diagnosis.

 wants to hear from you. What percentage of the global population is estimated to have hyperhidrosis?

 to share your hyperhidrosis insights or research.

Albert. Fact check: Hyperhidrosis - International Hyperhidrosis Society: Official site. Home - International Hyperhidrosis Society. October 24, 1970. Accessed November 16, 2023. 

https://www.sweathelp.org/home/news-blog/542-fact-check-hyperhidrosis.html

Hyperhidrosis affects approximately 385 million people globally, surpassing the prevalence of other dermatologic conditions like psoriasis. It is notably more common in younger populations, with 8.8% of individuals aged 18 to 39 experiencing the condition. Comparatively, hyperhidrosis is more prevalent than natural red or blond hair, which affects 1% and 2% of the population, respectively. Despite its prevalence, 27% of those with hyperhidrosis remain undiagnosed. The article encourages engagement during Hyperhidrosis Awareness Month to share insights and research on the condition.

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

POLL: What Percent of the Global Population is Estimated to Have Hyperhidrosis?

At the recent Society for Investigative Dermatology Annual Meeting, researchers shared new data demonstrating that TRIV-509, a novel monoclonal antibody targeting the serine proteases KLK5 and KLK7, may offer a rapid and effective therapeutic approach for atopic dermatitis (AD).

 The findings, presented in a poster highlight a promising avenue for restoring skin barrier integrity and reducing inflammation in patients.

Increasing evidence links dysregulation of epidermal serine proteases to the pathogenesis of AD, with KLK5 and KLK7, or kallikrein-related peptidases, playing pivotal roles.

 These enzymes are typically involved in skin desquamation but are overexpressed and hyperactive in atopic skin, leading to excessive degradation of critical barrier proteins such as desmoglein-1 (DSG1) and other structural components.

 Furthermore, variations that lead to increased KLK activity correlate with heightened susceptibility to AD and asthma.

The investigation involved collecting skin biopsies from 3 patients with clinically diagnosed AD, characterized by an Investigator Global Assessment (IGA) score greater than 2, indicative of moderate to severe disease activity. The experimental setup involved treating these biopsies with TRIV-509 or control IgG ex vivo.

The biopsies underwent treatment with 25 µg/mL of TRIV-509 for a period of 72 hours, with media changed at 48 hours and treatment renewed for an additional 24 hours. Subsequently, the tissues were processed for various analyses, including histological staining and immunohistochemistry, to assess changes in epidermal thickness, keratinocyte proliferation, and the expression of key structural proteins like DSG1.

One of the primary outcomes was a significant decrease in epidermal hyperplasia. In 2 patients, treatment with TRIV-509 resulted in a 14% to 28% reduction in epidermal thickness compared to control IgG. 

This reduction correlated with diminished keratinocyte proliferation, demonstrated by an approximately 80% decrease in Ki-67 positive basal layer cells, highlighting a substantial decrease in epidermal hyperproliferation.

TRIV-509 effectively mitigated parakeratosis, reducing abnormal nuclei layers in the stratum corneum by 31% in 1 of the patients. Additionally, histological evaluation revealed that the treatment restored the distribution and expression of DSG1 with a notable increase of up to 313% in DSG1+ cell counts in treated specimens. This suggests a rapid reestablishment of cell-cell adhesion and barrier function.

Further analyses demonstrated that TRIV-509 increased DSG1 expression in the epidermis, aligning it more closely with non-lesional skin. The treatment also reduced epidermal thickness and parakeratosis substantially, indicating improved epidermal differentiation and barrier integrity.

The findings presented at SID suggest that targeting KLK5 and KLK7 with an antibody such as TRIV-509 can rapidly reverse key features of the atopic epidermal phenotype. The therapy not only reduced hyperproliferation and keratinocyte turnover but also directly improves barrier integrity by restoring DSG1 levels.

Moving forward, researchers plan to evaluate TRIV-509 in clinical trials, with a focus on skin barrier improvements, symptom alleviation, and quality-of-life outcomes for patients with AD. The data also encourage further exploration into protease-targeted therapies for other barrier-related skin conditions.

Mateer E, Asp E, e Sousa MS, et al. TRIV-509, a dual inhibitor of KLK5 and KLK7, rapidly improves barrier integrity and markers of epidermal differentiation in atopic dermatitis skin explants. Poster presented at: Society for Investigative Dermatology Annual Meeting; May 7-10; San Diego, California.

Kishibe M. Physiological and pathological roles of kallikrein-related peptidases in the epidermis. 

Elias PM. Therapeutic implications of a barrier-based pathogenesis of atopic dermatitis. 

TRIV-509, a novel monoclonal antibody targeting serine proteases KLK5 and KLK7, shows promise as a rapid and effective treatment for atopic dermatitis (AD). By inhibiting these enzymes, TRIV-509 reduces epidermal hyperplasia, keratinocyte proliferation, and parakeratosis, while restoring DSG1 expression and skin barrier integrity. The study involved ex vivo treatment of skin biopsies from AD patients, demonstrating significant improvements in epidermal structure and function. Future clinical trials will focus on evaluating TRIV-509's impact on skin barrier improvements, symptom relief, and quality of life for AD patients.

Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.

Alexandra Kimball, MD

Articles

Latest Updated Articles